467 citations
,
October 2014 in “European Journal of Endocrinology” This paper reviews the diagnostic criteria, etiological factors, and treatment approaches for PCOS, highlighting the importance of considering metabolic issues such as insulin resistance and obesity, but reports no new findings.
59 citations
,
May 2014 in “Expert Opinion on Therapeutic Targets” This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.
1265 citations
,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.
90 citations
,
February 2013 in “The Journal of Clinical Endocrinology and Metabolism” This study found that women with polycystic ovary syndrome have higher global adiposity and increased visceral fat, particularly in the ip and mesenteric depots, compared to women without androgen excess.
58 citations
,
January 2013 in “The Journal of Clinical Endocrinology and Metabolism” This study suggests that sexual dimorphism in adipose tissue functions may be linked to androgen levels, as women with PCOS demonstrated a more masculine adipokine expression pattern.
39 citations
,
September 2012 in “Human Reproduction” This study found that specific SHBG gene variants, rs727428 and rs6259, were associated with PCOS in Mediterranean women, although the associations were relatively weak and do not indicate a causative role.
70 citations
,
February 2012 in “Human Reproduction” This study found a high prevalence of clinical signs and functional disorders of androgen excess in premenopausal women, with idiopathic hyperandrogenism and idiopathic hirsutism rates similar to PCOS.
63 citations
,
January 2012 in “The European Journal of Contraception & Reproductive Health Care” This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.
50 citations
,
March 2011 in “European Journal of Endocrinology” This study found that spironolactone treatment can normalize endothelial function and improve cholesterol levels in non-obese patients with polycystic ovary syndrome.
815 citations
,
April 2010 in “The Journal of Clinical Endocrinology & Metabolism” This review examines the relationship between polycystic ovary syndrome and cardiovascular disease risk, but reports no new clinical findings; the panel calls for guidelines to prevent CVD in this population.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
33 citations
,
January 2009 in “Contraception” This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.
121 citations
,
April 2008 in “The Journal of Clinical Endocrinology & Metabolism” Insulin sensitizers may slightly reduce hirsutism but are less effective than other treatments.
22 citations
,
February 2008 in “Biochemical and Biophysical Research Communications” Androgen effects on hair follicles vary by skin area.
150 citations
,
February 2008 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.
75 citations
,
November 2007 in “Clinical endocrinology” This study found that several drugs, including flutamide and spironolactone, significantly reduced hirsutism in women, with reduced effectiveness in those with higher BMI.
166 citations
,
March 2007 in “Hypertension” In this study, hyperandrogenemia in young women with polycystic ovary syndrome was linked to higher blood pressure, independent of factors like age, insulin resistance, obesity, or dyslipidemia.
1744 citations
,
August 2006 in “The Journal of Clinical Endocrinology and Metabolism” This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.
451 citations
,
March 2005 in “Endocrine Reviews” This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.
4025 citations
,
December 2003 in “Human Reproduction” This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.
61 citations
,
December 2001 in “Journal of Investigative Dermatology” This study found that steroid sulfatase in the dermal papilla of hair follicles metabolizes dehydroepiandrosterone sulfate to support the development of androgenetic alopecia, suggesting potential for steroid sulfatase inhibitors as treatments.
25 citations
,
September 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.
67 citations
,
February 1997 in “Teratology” This study demonstrated that high oral doses of finasteride caused external genital abnormalities in male rhesus monkey fetuses, but intravenous doses did not lead to abnormalities.
96 citations
,
October 1987 in “The Journal of Clinical Endocrinology & Metabolism” This study found that long-term GnRH agonist administration in premenopausal women with polycystic ovarian disease resulted in persistent suppression of ovarian steroid secretion, while adrenal steroid levels remained unchanged.
64 citations
,
March 1984 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” In this study, cyproterone acetate combined with estradiol dramatically improved hirsutism symptoms and significantly reduced plasma testosterone and androstenedione levels in patients over periods of up to three years.
